Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Adamis Pharmaceuticals Corp announces closing of public offering of common stock


Wednesday, 18 Dec 2013 11:54am EST 

Adamis Pharmaceuticals Corp:Says the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.Says the gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.Says it intends to use about $7 mln to make the final payment to acquire the assets relating to the Taper dry powder inhaler technology.Says an additional about $7.2 mln of the net proceeds are also expected to be used to pay in full all amounts owed under unconverted convertible promissory notes.Says the remaining net proceeds are expected to be used to fund efforts to obtain regulatory approval for and launch the company's products and for general purposes.Says CRT Capital Group, LLC acted as sole book-running manager for the offering, and Newport Coast Securities, Inc. acted as co-manager of the offering. 

Company Quote

5.36
 --
17 Dec 2014